Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Adis, Springer Healthcare
2025-01-01
|
| Schriftenreihe: | Drugs - Real World Outcomes |
| Online-Zugang: | https://doi.org/10.1007/s40801-024-00477-4 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|